Osiris Therapeutics, Inc. (NASDAQ:OSIR)

CAPS Rating: 1 out of 5

A stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.

Recs

1
Player Avatar TMFBlacknGold (98.56) Submitted: 9/26/2012 10:03:13 PM : Underperform Start Price: $10.01 OSIR Score: -4.17

Hopefully this speculative pharma red-thumb doesn't hurt me like some others have these past few months. (http://caps.fool.com/Blogs/biopharma-run-up-is-ruining-my/763269) I tend to agree with those who are realistic about the company's recent nod on Prochymal and ask "Yeah, so what?" This is tough for me because I am an absolute believer in the gargantuan impact stem cells will one day have on society. However, there are still too many obstacles and questions that remained to be answered. Maybe in a few years OSIR and ATHX will be on a less risky road.

Featured Broker Partners


Advertisement